IO Biotech, Inc. (OTCPK: IOBT.Q)
Health Care · Biotechnology · DK
$0.00
-95.00% today · -100.0% 1Y
IO Biotech, Inc. (OTCPK: IOBT.Q) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.20K and employs 80 people.
Over the last twelve months the share price has lost 100.0%, trading between 0.00 and 2.08.
Tweenvest scores IO Biotech, Inc. across four factors: quality 26/100. Its strongest factor is quality.
IOBT.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.20K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.34
- Dividend yield
- —
- Beta (5Y)
- -0.08
- 52-week high
- $2.08
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 71.95M
- Employees
- 80
- Next earnings
- —
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
- Founded
- 2014
- Listed since
- Nov 5, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.66 | +0.64% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.00 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €875.60 | -2.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $144.51 | -0.39% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.